Document and Entity Information |
Jun. 26, 2026 |
|---|---|
| Cover [Abstract] | |
| Amendment Flag | true |
| Entity Central Index Key | 0001662774 |
| Document Type | 8-K/A |
| Document Period End Date | Jun. 26, 2026 |
| Entity Registrant Name | QUINCE THERAPEUTICS, INC. |
| Entity Incorporation State Country Code | DE |
| Entity File Number | 001-38890 |
| Entity Tax Identification Number | 90-1024039 |
| Entity Address, Address Line One | 611 Gateway Boulevard |
| Entity Address, Address Line Two | Suite 273 |
| Entity Address, City or Town | South San Francisco |
| Entity Address, State or Province | CA |
| Entity Address, Postal Zip Code | 94080 |
| City Area Code | (415) |
| Local Phone Number | 910-5717 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Security 12b Title | Common Stock, par value $0.001 per share |
| Trading Symbol | QNCX |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |
| Amendment Description | This Current Report on Form 8-K/A (this “Amendment”) amends the Current Report on Form 8-K filed with the Securities and Exchange Commission on June 26, 2026 (the “Original Form 8-K”) by Quince Therapeutics, Inc. The sole purpose of this Amendment is to correct the description of the reverse stock split described in Item 3.03 of the Original Form 8-K. This Current Report on Form 8-K/A hereby amends and restates in its entirety Item 3.03 of the Original Form 8-K to correct the error. The Original Form 8-K otherwise remains unchanged. |